Showing results (61-70 of 164) with videos related to

Sort By:
Pageof 17
Bollettino Dell'Istituto Sieroterapico Milanese|January 1, 1988
[Epidemiological and clinical study on bee venom allergy among beekeepers]E A Pastorello, C Incorvaia, A Sarassi, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|May 19, 2005
The safety of sublingual-swallow immunotherapy: an analysis of published studiesG B Gidaro, F Marcucci, L Sensi, et al.
Monaldi Archives for Chest Disease = Archivio Monaldi Per Le Malattie Del Torace|May 17, 2006
Dose dependence of efficacy and safety of subcutaneous immunotherapyC Incorvaia, F Frati, P Puccinelli, et al.
Allergy|October 1, 1992
Clinical evaluation of CAP System and RAST in the measurement of specific IgEE A Pastorello, C Incorvaia, V Pravettoni, et al.
Minerva Pediatrica|August 1, 1989
[Allergy to Hymenoptera venom in children. Diagnosis and therapy]E A Pastorello, C Incorvaia, A Sarassi, et al.
New England and Regional Allergy Proceedings|November 1, 1987
Allergen specific IgG subclass antibody response in hyposensitization with Dermatophagoides pteronyssinus extractE A Pastorello, C Incorvaia, A Gerosa, et al.
Allergy|October 27, 1998
Atopy and intolerance of antimicrobial drugs increase the risk of reactions to acetaminophen and nimesulide in patients allergic to nonsteroidal anti-inflammatory drugsE A Pastorello, C Zara, G G Riario-Sforza, et al.
European Annals of Allergy and Clinical Immunology|April 28, 2020
The role of allergoids in allergen immunotherapy: from injective to sublingual routeE Compalati, C Incorvaia, C Cavaliere, et al.
Ophthalmologica. Journal International D'Ophtalmologie. International Journal of Ophthalmology. Zeitschrift Fur Augenheilkunde|January 1, 1995
Effects of the passive transfer of anti-gB antibodies in a rabbit model of HSV-1-induced keratitisC Incorvaia, R Manservigi, F Parmeggiani, et al.
European Annals of Allergy and Clinical Immunology|November 18, 2016
Comparing the compliance to a short schedule of subcutaneous immunotherapy and to sublingual immunotherapy during three years of treatmentG Manzotti, G G Riario-Sforza, M Dimatteo, et al.
Pageof 17